#Sweden #Lund #pancreatic cancer #Immunovia AB #warrants TO 2

Immunovia AB Concludes Warrant Series TO 2

In a significant development for Immunovia AB, the company recently announced the successful conclusion of its warrants series TO 2. The exercise period, which ran from January 2 to January 16, 2025, saw an impressive participation rate of approximately 74.1% from investors. A total of 92,197,387 warrants were converted, resulting in the issuance of an equivalent number of new shares.

This move has reinforced Immunovia's financial position, allowing the company to generate approximately 42.4 million SEK before incurring issue costs. Such capital is pivotal not only for the company’s operational stability but also for accelerating research and development, especially regarding their next-generation diagnostic tests aimed at detecting pancreatic cancer.

Jeff Borcherding, CEO of Immunovia, expressed gratitude towards shareholders who participated, stating, “We appreciate the investment in Immunovia. This capital will enable us to enhance our preparations for launching our cutting-edge test in the US market later this year.” He further emphasized that the funds would support additional clinical data generation required for test reimbursement, highlighting the significance of thorough validation in clinical settings for any diagnostic innovation.

With the recent exercises, Immunovia's share count has increased from 169,711,476 to 261,908,863, while the company's share capital rose to 7,857,265.89 SEK. However, this expansion brings along a dilution effect amounting to approximately 35.2% for existing shareholders who opted not to exercise their warrants.

Interim Shares to Be Converted

As part of the warrant exercise process, the newly created shares will initially be represented as interim shares (IA) until they are fully registered with the Swedish Companies Registration Office. The conversion into standard shares is anticipated to happen within the next two weeks.

Market Context and Future Prospects

The market for pancreatic cancer diagnostics holds vast potential, particularly in the United States, which Immunovia identifies as the world's largest market for such medical interventions. It is estimated that 1.8 million individuals in the U.S. are at high risk for pancreatic cancer, necessitating annual surveillance through innovative blood-based tests that Immunovia is developing. Their core mission revolves around increasing survival rates for patients diagnosed with pancreatic cancer through early detection methods, which could substantially alter the prognosis for these patients.

Immunovia collaborates closely with healthcare providers, leading medical experts, and patient advocacy groups to promote access to its diagnostic tests. By engaging directly with key stakeholders in the healthcare ecosystem, the company aims to ensure that their groundbreaking technologies reach the individuals who need them most.

Advisors and Contacts

For those interested in the specifics of this financing initiative, Vator Securities AB acted as the financial adviser, with Setterwalls providing legal assistance to Immunovia during the warrant exercise process. Questions related to the exercise and Immunovia’s future strategies can be directed to Jeff Borcherding, CEO, or Karin Almqvist Liwendahl, CFO. Their proactive communication and engagement strategies reflect the company’s commitment to transparency and shareholder relations.

Immunovia, with its innovative approaches to cancer diagnostics, continues to pave the way for significant advancements in early cancer detection, setting the stage for improved patient outcomes and pioneering medical practices in oncology. Stay tuned for more updates as the company progresses towards its launch of new tests and expands its market reach.

For additional insights into Immunovia's initiatives or for investor relations, please visit Immunovia’s official website.